Antibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate Transmission

Abnormal deposition and intercellular propagation of α-synuclein plays a central role in the pathogenesis of disorders such as Parkinson's Disease (PD) and dementia with Lewy bodies (DLB). Previous studies demonstrated that immunization against α-synuclein resulted in reduced α-synuclein accumulation and synaptic loss in a transgenic (tg) mouse model, highlighting the potential for immunotherapy. However, the mechanism by which immunization prevents synucleinopathy-associated deficits remains unknown. Here, we show that antibodies against α-synuclein specifically target and aid in clearance of extracellular α-synuclein proteins by microglia, thereby preventing their actions on neighboring cells. Antibody-assisted clearance occurs mainly in microglia through the Fcγ receptor, and not in neuronal cells or astrocytes. Stereotaxic administration of antibody into the brains of α-synuclein tg mice prevented neuron-to-astroglia transmission of α-synuclein and led to increased localization of α-synuclein and the antibody in microglia. Furthermore, passive immunization with α-synuclein antibody reduced neuronal and glial accumulation of α-synuclein and ameliorated neurodegeneration and behavioral deficits associated with α-synuclein overexpression. These findings provide an underlying mechanistic basis for immunotherapy for PD/DLB and suggest extracellular forms of α-synuclein as potential therapeutic targets.

[1]  P. Diggle,et al.  Phosphorylated α‐synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  L. Lannfelt,et al.  Antibodies against Alpha-Synuclein Reduce Oligomerization in Living Cells , 2011, PloS one.

[3]  R. LaMotte,et al.  Neuronal Fc-gamma receptor I mediated excitatory effects of IgG immune complex on rat dorsal root ganglion neurons , 2011, Brain, Behavior, and Immunity.

[4]  J. Kordower,et al.  Transfer of host-derived alpha synuclein to grafted dopaminergic neurons in rat , 2011, Neurobiology of Disease.

[5]  Y. Yun,et al.  Enzyme-linked immunosorbent assays for alpha-synuclein with species and multimeric state specificities , 2011, Journal of Neuroscience Methods.

[6]  E. Masliah,et al.  Protein aggregate spreading in neurodegenerative diseases: Problems and perspectives , 2011, Neuroscience Research.

[7]  Ji-Eun Suk,et al.  Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers , 2011, Experimental & Molecular Medicine.

[8]  E. Masliah,et al.  Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease , 2011, PloS one.

[9]  Rolandas Meskys,et al.  α-Synuclein Reactive Antibodies as Diagnostic Biomarkers in Blood Sera of Parkinson's Disease Patients , 2011, PloS one.

[10]  J. Gu,et al.  Expression and distribution of immunoglobulin G and its receptors in the human nervous system. , 2011, The international journal of biochemistry & cell biology.

[11]  Christian Münch,et al.  Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells , 2011, Proceedings of the National Academy of Sciences.

[12]  P. Brundin,et al.  α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. , 2011, The Journal of clinical investigation.

[13]  B. Hyman,et al.  Heat‐shock protein 70 modulates toxic extracellular α‐synuclein oligomers and rescues trans‐synaptic toxicity , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  Igor Tsigelny,et al.  Cell-to-cell transmission of non-prion protein aggregates , 2010, Nature Reviews Neurology.

[15]  Mark H. Ellisman,et al.  Alterations in mGluR5 Expression and Signaling in Lewy Body Disease and in Transgenic Models of Alpha-Synucleinopathy – Implications for Excitotoxicity , 2010, PloS one.

[16]  B. Mollenhauer,et al.  Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. , 2010, Biomarkers in medicine.

[17]  H. Gendelman,et al.  Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases , 2010, Journal of neurochemistry.

[18]  D. Loeffler,et al.  Specific antibodies to soluble alpha‐synuclein conformations in intravenous immunoglobulin preparations , 2010, Clinical and experimental immunology.

[19]  Ji-Eun Suk,et al.  Non‐classical exocytosis of α‐synuclein is sensitive to folding states and promoted under stress conditions , 2010, Journal of neurochemistry.

[20]  M. Ntzouni,et al.  Cell-Produced α-Synuclein Is Secreted in a Calcium-Dependent Manner by Exosomes and Impacts Neuronal Survival , 2010, The Journal of Neuroscience.

[21]  E. Masliah,et al.  Can Alzheimer disease be prevented by amyloid-β immunotherapy? , 2010, Nature Reviews Neurology.

[22]  F. Barrero,et al.  Plasma α‐synuclein in patients with Parkinson's disease with and without treatment , 2010, Movement disorders : official journal of the Movement Disorder Society.

[23]  E. Masliah,et al.  Direct Transfer of α-Synuclein from Neuron to Astroglia Causes Inflammatory Responses in Synucleinopathies* , 2010, The Journal of Biological Chemistry.

[24]  E. Masliah,et al.  Beclin 1 Gene Transfer Activates Autophagy and Ameliorates the Neurodegenerative Pathology in α-Synuclein Models of Parkinson's and Lewy Body Diseases , 2009, The Journal of Neuroscience.

[25]  Brian Spencer,et al.  Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein , 2009, Proceedings of the National Academy of Sciences.

[26]  Martin Beibel,et al.  Transmission and spreading of tauopathy in transgenic mouse brain , 2009, Nature Cell Biology.

[27]  M. Diamond,et al.  Propagation of Tau Misfolding from the Outside to the Inside of a Cell* , 2009, Journal of Biological Chemistry.

[28]  M. Cookson α-Synuclein and neuronal cell death , 2009, Molecular Neurodegeneration.

[29]  D. Holtzman,et al.  Rapid Microglial Response Around Amyloid Pathology after Systemic Anti-Aβ Antibody Administration in PDAPP Mice , 2008, The Journal of Neuroscience.

[30]  He-Jin Lee,et al.  Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. , 2008, Biochemical and biophysical research communications.

[31]  Seth Love,et al.  Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.

[32]  R. Hauser,et al.  Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease , 2008, Nature Medicine.

[33]  Elisabet Englund,et al.  Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation , 2008, Nature Medicine.

[34]  Sandra Lynch,et al.  An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. , 2008, Journal of molecular biology.

[35]  Armin Giese,et al.  Different Species of α-Synuclein Oligomers Induce Calcium Influx and Seeding , 2007, The Journal of Neuroscience.

[36]  David S. Miller,et al.  Microglial PHOX and Mac‐1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha‐synuclein , 2007, Glia.

[37]  M. Sierks,et al.  Isolation of a human single chain antibody fragment against oligomeric α-synuclein that inhibits aggregation and prevents α-synuclein induced toxicity , 2007 .

[38]  M. Horne,et al.  Plasma α-synuclein is decreased in subjects with Parkinson's disease , 2007, Experimental Neurology.

[39]  J. Julien,et al.  Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis , 2007, Proceedings of the National Academy of Sciences.

[40]  V. Buchman,et al.  Autoantibodies to alpha‐synuclein in inherited Parkinson’s disease , 2006, Journal of neurochemistry.

[41]  D. Allsop,et al.  Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[42]  S. M. Park,et al.  Proteolytic Cleavage of Extracellular Secreted α-Synuclein via Matrix Metalloproteinases* , 2005, Journal of Biological Chemistry.

[43]  Smita Patel,et al.  Intravesicular Localization and Exocytosis of α-Synuclein and its Aggregates , 2005, The Journal of Neuroscience.

[44]  Makoto Hashimoto,et al.  Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease , 2005, Neuron.

[45]  J. Bijlsma,et al.  Down-regulation of activating Fcgamma receptors on monocytes of patients with rheumatoid arthritis upon methotrexate treatment. , 2005, Rheumatology.

[46]  E. Masliah,et al.  Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease , 2005, Neurology.

[47]  S. Malawista,et al.  Recruitment of the cross-linked opsonic receptor CD32A (FcgammaRIIA) to high-density detergent-resistant membrane domains in human neutrophils. , 2004, The Biochemical journal.

[48]  R. Simari,et al.  Selective stimulation of caveolar endocytosis by glycosphingolipids and cholesterol. , 2004, Molecular biology of the cell.

[49]  He-Jin Lee,et al.  Clearance of α-Synuclein Oligomeric Intermediates via the Lysosomal Degradation Pathway , 2004, The Journal of Neuroscience.

[50]  Y. Kuraishi,et al.  Direct action of immunoglobulin G on primary sensory neurons through Fc gamma receptor I , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[51]  M. Cookson,et al.  α‐Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[52]  D. Dickson,et al.  Amyloid-β Immunization Effectively Reduces Amyloid Deposition in FcRγ-/- Knock-Out Mice , 2003, The Journal of Neuroscience.

[53]  B. Dubois,et al.  Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization , 2003, Neurology.

[54]  G. Saggese,et al.  Pubertal Changes in Biochemical Markers of Growth , 2003, Hormone Research in Paediatrics.

[55]  J. Collinge,et al.  Monoclonal antibodies inhibit prion replication and delay the development of prion disease , 2003, Nature.

[56]  K. Kwiatkowska,et al.  Phosphorylation of FcγRIIA is required for the receptor-induced actin rearrangement and capping: the role of membrane rafts , 2003, Journal of Cell Science.

[57]  Seung-Jae Lee,et al.  Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. , 2002, The Journal of biological chemistry.

[58]  B. Hyman,et al.  Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β In Vivo by Immunotherapy , 2002, The Journal of Neuroscience.

[59]  Makoto Hashimoto,et al.  Differential neuropathological alterations in transgenic mice expressing α‐synuclein from the platelet‐derived growth factor and Thy‐1 promoters , 2002, Journal of neuroscience research.

[60]  P. Sun,et al.  Recognition of immunoglobulins by Fcγ receptors , 2002 .

[61]  S. Naccache,et al.  Early Events in the Activation of FcγRIIA in Human Neutrophils: Stimulated Insolubilization, Translocation to Detergent-Resistant Domains, and Degradation of FcγRIIA1 , 2002, The Journal of Immunology.

[62]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[63]  R. Motter,et al.  Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.

[64]  L. Mucke,et al.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. , 2000, Science.

[65]  H. Heiken,et al.  The IgG Fc receptor family , 1998, Annals of Hematology.

[66]  D. Galasko,et al.  CSF Tau and Aβ42: Logical Biomarkers for Alzheimer’s Disease? , 1998, Neurobiology of Aging.

[67]  Akihiko Iwai,et al.  The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system , 1995, Neuron.

[68]  E. Sigurdsson Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. , 2008, Journal of Alzheimer's disease : JAD.

[69]  Seung-Jae Lee Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease. , 2008, Journal of molecular neuroscience : MN.

[70]  He-Jin Lee,et al.  Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. , 2008, The international journal of biochemistry & cell biology.

[71]  M. Horne,et al.  Plasma alpha-synuclein is decreased in subjects with Parkinson's disease. , 2007, Experimental neurology.

[72]  M. Sierks,et al.  Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. , 2007, Journal of molecular biology.

[73]  Seung-Jae Lee Origins and Effects of Extracellular α-synuclein: Implications in Parkinson’s Disease , 2007, Journal of Molecular Neuroscience.

[74]  Armin Giese,et al.  Different species of alpha-synuclein oligomers induce calcium influx and seeding. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[75]  S. M. Park,et al.  Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases. , 2005, The Journal of biological chemistry.

[76]  E. Masliah,et al.  Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. , 2005, Neuron.

[77]  He-Jin Lee,et al.  Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[78]  D. Dickson,et al.  Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. , 2003, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[79]  S. Naccache,et al.  Early events in the activation of Fc gamma RIIA in human neutrophils: stimulated insolubilization, translocation to detergent-resistant domains, and degradation of Fc gamma RIIA. , 2002, Journal of Immunology.

[80]  P. Sun,et al.  Recognition of immunoglobulins by Fcgamma receptors. , 2002, Molecular immunology.

[81]  J. V. Ravetch,et al.  IgG Fc receptors. , 2001, Annual review of immunology.

[82]  D. Galasko CSF tau and Abeta42: logical biomarkers for Alzheimer's disease? , 1998, Neurobiology of Aging.